| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Profilin Blocking Peptide for STJ506120 is synthetically produced from the 50-100 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
PFN1 |
| Gene ID: |
5216 |
| Uniprot ID: |
PROF1_HUMAN |
| Immunogen Region: |
50-100 |
| Specificity: |
This blocking peptide is recommended for use in combination with Profilin antibody, STJ506120 |
| Immunogen: |
Synthetic peptide corresponding to amino acids within region 50-100 on human Profilin 1. |
| Tissue Specificity | Expressed in epididymis (at protein level). |
| Post Translational Modifications | Phosphorylation at Ser-138 reduces its affinity for G-actin and blocks its interaction with HTT, reducing its ability to inhibit androgen receptor (AR) and HTT aggregation. |
| Function | Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG. Inhibits androgen receptor (AR) and HTT aggregation and binding of G-actin is essential for its inhibition of AR. |
| Peptide Name | Profilin-1Epididymis Tissue Protein Li 184aProfilin I |
| Database Links | Reactome: R-HSA-114608Reactome: R-HSA-376176Reactome: R-HSA-4086400Reactome: R-HSA-5663220 |
| Cellular Localisation | CytoplasmCytoskeleton |
| Alternative Peptide Names | Profilin-1 proteinEpididymis Tissue Protein Li 184a proteinProfilin I proteinPFN1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
